Pediatric Ethics Subcommittee
Protocol for National Heart Blood & Lung Institute-sponsored study of surfactant synthesis in newborns will be evaluated by FDA's Pediatric Ethics Subcommittee on June 28. The protocol was rejected by the Washington University institutional review board because there would be no direct benefit to the pediatric patients involved in the study of surfactant precursors. The meeting will be held in the CDER advisory committee conference room at 5630 Fishers Lane in Rockville, Md. beginning at 8:30 a.m...
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.